GlassScriptPhysician profile
Lee Ming Wong
NPI 1730382797
$2,649.58
in general payments reported to CMS, 2019-2025
17 companies · $867 in 2025
The $867 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $236 · 2021: $239 · 2022: $273 · 2023: $282 · 2024: $540 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,689.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $484.28 | 2024-2025 | Xiidra, Miebo, Vyzulta |
| Allergan, INC. | $392.06 | 2019-2022 | |
| Oyster Point Pharma, INC. | $311.17 | 2022-2025 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $237.01 | 2019-2025 | Precision7, Clareon, Tryptyr |
| Glaukos Corporation | $189.53 | 2025 | Idosetr, Istent Infinite |
| Sun Pharmaceutical Industries INC. | $176.51 | 2020-2023 | Cequa |
| Eyevance Pharmaceuticals LLC | $165.70 | 2021 | |
| Harrow Eye, LLC | $155.96 | 2024-2025 | Vevye |
| Abbvie INC. | $139.58 | 2023-2025 | Vuity |
| Tarsus Pharmaceuticals, INC. | $131.87 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $77.65 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $75.56 | 2021-2025 | Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $42.97 | 2019-2020 | |
| Ocular Therapeutix, INC. | $27.70 | 2021-2024 | Dextenza |
| Kala Pharmaceuticals, INC. | $14.31 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $14.30 | 2021 | |
| Shire North American Group INC | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.